Resistance to Anticancer Agents: Recent Trends

Ahmed M. Kabel^{1, 2,} and Maaly A. Abd Elmaaboud²

¹Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

²Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

Cite this paper:
Ahmed M. Kabel and Maaly A. Abd Elmaaboud. Resistance to Anticancer Agents: Recent Trends. Journal of Cancer Research and Treatment. 2020; 8(2):11-14. doi: 10.12691/jcrt-8-2-1

Abstract

Resistance to the anticancer agents is a complex process that mainly results from alteration in the targets of the chemotherapeutic agents. Mechanisms that underlie resistance to the anticancer agents include inactivation of the drug, inhibition of cellular apoptosis, changes in the metabolic pathways of the drug, increased expression of the efflux proteins and enhancement of DNA repair and gene amplification. Several strategies were developed to overcome this resistance. The use of the combination chemotherapy is the best option for drug resistant types of cancer. This review throws light on resistance of cancer cells to the chemotherapeutic agents in view of the recent trends.

Keywords:
cancer multi-drug resistance anticancer agents management

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Kabel AM, Abd Elmaaboud MA. Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management. World Journal of Nutrition and Health. 2014; 2(4): 48-51.
[2]	Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull 2017; 7(3): 339-348.
[3]	Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis 2018; 35(4): 309-318.
[4]	Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Line A, Machuqueiro M, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat 2019; 46: 100645.
[5]	Alfarouk KO, Stock CM, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int 2015; 15:71.
[6]	Wojtuszkiewicz A, Peters GJ, van Woerden NL, et al. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. J Hematol Oncol 2015; 8:61.
[7]	Xiong J, Feng J, Yuan D, Zhou J, Miao W. Tracing the structural evolution of eukaryotic ATP binding cassette transporter superfamily. Sci Rep 2015; 5: 16724.
[8]	Kabel AM, Atef A, Estfanous RS. Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma. Biomed Pharmacother 2018; 97: 667-674.
[9]	Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 2018;3:7.
[10]	Levin M, Stark M, Berman B, Assaraf YG. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine. Cell Death Dis 2019; 10(6): 390.
[11]	Dong SC, Sha HH, Xu XY, et al. Glutathione S-transferase π: a potential role in antitumor therapy. Drug Des Devel Ther 2018; 12: 3535-3547.
[12]	Pljesa-Ercegovac M, Savic-Radojevic A, Matic M, et al. Glutathione Transferases: Potential Targets to Overcome Chemoresistance in Solid Tumors. Int J Mol Sci 2018; 19(12): 3785.
[13]	Rathore R, McCallum JE, Varghese E, Florea AM, Büsselberg D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 2017; 22(7): 898-919.
[14]	García-Aranda M, Pérez-Ruiz E, Redondo M. Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy. Int J Mol Sci 2018; 19(12): 3950.
[15]	Dou Y, Jiang X, Xie H, He J, Xiao S. The Jun N-terminal kinases signaling pathway plays a "seesaw" role in ovarian carcinoma: a molecular aspect. J Ovarian Res 2019; 12(1): 99.
[16]	van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. Cancer Chemother Pharmacol 2019; 84(3): 487-499.
[17]	Rahman M, Hasan MR. Cancer Metabolism and Drug Resistance. Metabolites 2015; 5(4): 571-600.
[18]	Delgado JL, Hsieh CM, Chan NL, Hiasa H. Topoisomerases as anticancer targets. Biochem J 2018; 475(2): 373-398.
[19]	Shagisultanova EI, Piao Z, Li HR, Malkhosyan SR. Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability. Cancer Lett 2004; 216(2): 221-226.
[20]	Davalli P, Marverti G, Lauriola A, D'Arca D. Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies. Oxid Med Cell Longev 2018; 2018: 2389523.
[21]	Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med 2015; 66: 129-143.
[22]	Damia G, Broggini M. Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers (Basel) 2019; 11(1): 119.
[23]	Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell 2017; 168(4): 670-691.
[24]	Yuan S, Lin LS, Gan RH, et al. Elevated matrix metalloproteinase 7 expression promotes the proliferation, motility and metastasis of tongue squamous cell carcinoma. BMC Cancer 2020; 20(1): 33.
[25]	Itatani Y, Kawada K, Sakai Y. Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment. Int J Mol Sci 2019; 20(23): 5822.
[26]	Bagci O, Kurtgöz S. Amplification of Cellular Oncogenes in Solid Tumors. N Am J Med Sci 2015; 7(8): 341-346.
[27]	Göker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995; 86(2): 677-684.
[28]	Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation 2011; 123(19): 2145-2156.
[29]	Miller JL, Grant PA. The role of DNA methylation and histone modifications in transcriptional regulation in humans. Subcell Biochem 2013; 61: 289-317.
[30]	Llinàs-Arias P, Esteller M. Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update. Open Biol 2017; 7(9):170152.
[31]	Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel) 2014; 6(3): 1769-1792.
[32]	Casals E, Gusta MF, Cobaleda-Siles M, Garcia-Sanz A, Puntes VF. Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles. Cancer Nanotechnol 2017; 8(1): 7.
[33]	Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011; 50(1): 209-232.
[34]	Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013; 18(1-2): 43-73.
[35]	Volm M, Efferth T. Prediction of Cancer Drug Resistance and Implications for Personalized Medicine. Front Oncol 2015;5:282.
[36]	Lippert TH, Ruoff HJ, Volm M. Current status of methods to assess cancer drug resistance. Int J Med Sci 2011; 8(3): 245-253.
[37]	Elshimali YI, Wu Y, Khaddour H, et al. Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 2018; 1(2): 107.
[38]	Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget 2017; 8(23): 38022-38043.
[39]	Chakraborty C, Sharma AR, Sharma G, Sarkar BK, Lee SS. The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget 2018; 9(11): 10164-10174.
[40]	Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev 2016; 98: 19-34.